Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

  • January 2017 •
  • Report ID: 4699207 •
  • Format: PDF
Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance


Bacteria are a major class of prokaryotic micro-organism and are broadly classified as either gram-positive bacteria, which retain their color under gram-staining and have an inner plasma membrane and a thick peptidoglycan layer, or gram-negative bacteria, which lose their color under gram-staining and have both an inner and outer plasma membrane with a thin peptidoglycan wall in-between these structures.

Antibacterial usage is expected to decrease slightly in developed countries as a result of an increasing pressure to combat antimicrobial resistance (AMR). Despite this, the antibacterial drug market is forecast to grow from USD27.7 Billion in 2015 to USD35.6 Billion in 2022, at a compound annual growth rate (CAGR) of 3.97%.

Antibacterial market is dominated by three players: Pfizer, GlaxoSmithKline (GSK) and Merck & Co. Pfizer is expected to maintain its lead in the market in terms of revenue and market share until 2022, while GSK and Merck & Co. are expected to experience substantial growth within antibacterial over the forecast period, helping to drive the growth of the market overall. A large part of this growth is expected to come from the entry into the market of several companies, including Allergan, Cempra and Insmed.

Global antibacterial vaccination market is expected to experience healthy growth across the forecast period due to rising profits for several classes of drugs. Vaccines will still be the leading revenue-generating drugs in the market in 2022, despite the influx of new protein synthesis inhibitors and the release of several new cell-wall synthesis inhibitors.

As per Thomas Jarratt, Analyst, “In an attempt to tackle antimicrobial resistance, many companies are investing in the development of products active against bacteria that are known to be resistant to established classes of antibacterials. The use of protein synthesis inhibitors, for example, is expected to increase dramatically over the forecast period as a result of their effectiveness in treating drug-resistant bacterial infections.”

The report “Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance” provides an introduction to the antibacterial market, including disease epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications, diagnosis and prognosis.

In depth, this report provides the following -
- Provides an overview of the landscape for antibacterial marketed products, including product profiles of key marketed products and revenue projections for each of these drugs.
- Analyzes the antibacterial pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and mechanism of action, plus an analysis of the key indications in the pipeline: pneumonia, TB, sepsis and methicillin-resistant staphylococcus aureus (MRSA).
- Presents forecast projections to 2022 on a global level, with forecasts also provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan.
- Assesses the company landscape in bacterial infections, with an analysis of the key players, the types of company involved in this disease cluster, and whether this disease cluster comprises a large proportion of each company’s pipeline portfolio and total revenue.
- Analysis about trends in co-development and licensing deals relating to antibacterial products.

Companies mentioned in this report: Merck & Co, GlaxoSmithKline, Pfizer.


Antibiotic resistance has caused a surge in the development of antibiotics:
- How big is the antibiotic pipeline?
- How are companies attempting to overcome antibiotic resistance?
The antibacterial drug market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022:
- How much will the approval of new products and the patent expiries of existing ones contribute to this market growth?
- Will vaccines continue to drive market revenue?
The pipeline contains a range of molecular targets:
- Which molecular targets are most popular in the current pipeline?
- How many late-stage products are active against drug-resistant bacteria?
- What are the commercial prospects for the most promising late-stage pipeline products?
Big Pharma maintains a strong presence within the antibacterial drug market:
- Which of the leading companies are expected to have the highest share of the market by 2022?
- Which of the leading pharmaceutical companies are expected to bring new products to market during the forecast period?
- Which companies rely heavily of revenues derived from antibacterial drugs?

Reasons to buy

- Understand the current clinical and commercial landscape through a comprehensive analysis of innovation in the antibacterial drug market in the context of the overall pipeline and current market landscape. It also includes analysis of the deals landscape, including both licensing deals and co-development deals. Key indications covered in detail include pneumonia, MRSA, sepsis and tuberculosis.
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the antibacterial pipeline through a comprehensive review of the pipeline, segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at antibacterial drug clinical trials, to provide an insight into the risk associated with attempting to bring pipeline antibacterial drugs to market.
- Predict growth in market size, with in-depth market forecasting from 2015 to 2022. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
- Identify the key pipeline products, with a particular focus on those due to be brought to market in the near future, as well as sales forecasts for these products.
- Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies in the market are on revenue derived from antibacterial products. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
- Assess the licensing and co-development deal landscape for antibacterial therapies.

We are very sorry, but an error occurred.
Please contact if the problem remains.